TAMs are usually polarized toward the tumor growth and progression promoting M2 phenotype characterized by a constant low‐level release of pro‐inflammatory cytokines on the one hand, and a reduced or defective TNF‐α and IL‐12 production and high IL‐10 secretion upon activation on the other side 14. The gene discussed is IL10; the disease is neoplasm.